ISSN: 2249-9504
CAS CODEN: IJPCDX

Abstracted and Indexed

open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing
+32 25889658
Google Scholar citation report
Citations : 3566

International Journal of Pharmaceutical, Chemical and Biological Sciences received 3566 citations as per google scholar report

International Journal of Pharmaceutical, Chemical and Biological Sciences peer review process verified at publons

ANTIDIABETIC ACTIVITY OF NEW IMIDAZOLE DERIVATIVE(2-(2-benzylidenehydrazinyl)-5,5-diphenyl-1,5-dihydro-4H-imidazol 4-one(C22 H17 N4OCl)

Abstract

Author(s): GE.Suhasini1, M. Nirmala1, DR. Archanagiri2, V.Varalaksmi1andB.Solomon sunder Raj3

The new imidazole chloro derivative was synthesized and evaluated for the nti diabetic activity, by inducing diabetes using alloxan. The study was conducted using rats in four groups with 6 in each. group one served as control, second group served as diabetic control, third group as standard and fourth for test sample. Glibenclamide was used as standard drug . Lipid profile was also studied. The study was conducted for 14 days. Then blood samples were tested on 1st, 3rd, 7th and 14th day. The blood Glucose Levels decreased significantly after the administration of test sample from 449mg/dl to 164mg/dl with p<0. 01 . total cholesterol, LDL cholesterol, triglycerides and VLDL decreased. HDL cholesterol increased. SGPT, SGOT serum glucose levels reduced p<0.01 As the synthesized compound has reduced blood glucose levels and lipid lowering potential this can be developed into hypoglycemic drug.

Get the App